EMPA Swiss Federal Laboratories for Material Testing and Research, Laboratory for Materials - Biology Interaction, St. Gallen, Switzerland.
Swiss Med Wkly. 2012 Apr 5;142:w13559. doi: 10.4414/smw.2012.13559. eCollection 2012.
Exposure of pregnant women and their unborn children to engineered nanoparticles (NPs) is not yet of major public concern. However, this may soon change in light of the ever-increasing production of NPs and the continuous appearance of novel NP-containing consumer products. However, NPs may not only pose risks to exposed individuals; they offer major potential for the development of novel therapeutic strategies to treat specifically either the mother or the developing foetus. Hence there is every reason to explore the transplacental transfer of engineered NPs in more detail, and to find answers to the vast number of open questions in this fascinating field of research.
孕妇及其未出生的孩子暴露于工程纳米粒子（NPs）目前尚未引起公众的广泛关注。然而，鉴于 NPs 的产量不断增加，以及新型含 NP 的消费产品不断涌现，这种情况可能很快就会改变。然而，NPs 不仅可能对暴露的个体构成风险，它们还为开发新型治疗策略提供了巨大的潜力，以专门治疗母亲或发育中的胎儿。因此，我们有充分的理由更详细地研究工程纳米粒子的胎盘转移，并为这一迷人的研究领域中的大量开放性问题找到答案。
